Sinsin Pharmaceutical

At a glance

Sinsin Pharmaceutical filed 20 disclosures in the last 12 months, including 1 insider and 1 5% holder. The most recent key filing was on Jul 1.

Revenue for 2025 was ₩114B, up 6.9% on 2024. Operating margin was 9.5% against 6.5% a year earlier. Debt was 85% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩64.2B and operating profit of ₩7.2B.

The 2025 annual report lists 369 employees with an average tenure of 6.7 years and average pay of ₩59.9M, #979 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩167M each on average. It paid ₩80 per common share in cash dividends, against ₩60 a year earlier (+33.3%). 이병기 and related parties held 51.50% at year end.

From the 2025 annual report

Staff: 369 (244 men, 125 women), of whom 11 on fixed-term contracts. Total pay for the year: ₩22.6B. Directors and auditors: 5, paid ₩834M in total.

Dividends (common shares)

Largest shareholder

이병기 holds 26.36%; with 9 related parties the group holds 51.50% of common shares at year end.

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary